P01 Central Mechanisms of Cortical Spreading Depression Inhibition by Vagus Nerve Stimulation
Morais, Andreia

P02 Cortical Spreading Depression Inhibition by Non-invasive Vagus Nerve Stimulation: Dose-response and Duration of Effect
Morais, Andreia

P03 Early Life Stress-induced Increases in Cortical Spreading Depression Susceptibility and Anxiety Are Not Expressed in the Progeny of Stressed Male Rats
Collins, Stuart

P04 Maternal Separation-induced Increases in CrhR1 Expression Within the Occipital Cortex and Hippocampus
Collins, Stuart

P05 Early Life Stress Promotes Development of a Sensitized Trigeminal System and Gut Dysbiosis That Is More Severe in Females
Durham, Paul

P06 Noninvasive Vagus Nerve Stimulation and Morphine Transiently Inhibit Trigeminal Pain Signaling in a Chronic Migraine Model
Durham, Paul

P07 The Role of Cerebellar CGRP in Migraine-like Behavior
Wang, Mengya

P08 Effect of Yoga as Add on Therapy in Migraine (CONTAIN): A Randomized Controlled Study
Kumar, Anand

P09 CGRP Antibodies as Adjunctive Prophylactic Therapy for Prolonging the Therapeutic Effect of OnabotulinumtoxinA Injections Among Chronic Migraine Patients
Yuan, Heidi

P10 A Real-world Assessment of the Impact on the Health-related Quality of Life and Work Productivity of Triptan Non-responders Compared with Responders: Results from a Global Study
Lombard, Louise

P11 Early Detection of Persons at Risk for Incident CM
Iaconangelo, Charles

P12 Eptinezumab Reduces the Frequency of Headaches and Migraines in Patients with Episodic or Chronic Migraine: Results from the PROMISE 1 and PROMISE 2 Trials
Mechtler, Laszlo

P13 OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study
Rothrock, John
The Impact of OnabotulinumtoxinA vs Placebo on Efficacy Outcomes in Responder and Nonresponder Subgroups of Patients with Chronic Migraine: PREEMPT Pooled Analysis
Diener, Hans-Christoph

Multiple Sclerosis and Headache: A Further Examination of These Comorbid Conditions in Patients Receiving Care in a Multiple Sclerosis Center: A Cross-Sectional Study
Minen, Mia

Reduced Impact of Headaches After Migraine Preventive Treatment with Eptinezumab in Patients with Chronic Migraine: Results from the PREVAIL Open-Label Safety Study
Spierings, Egilius

Eptinezumab Treatment for Migraine Prevention Reduces Migraine Disability in Patients with Chronic Migraine: An Analysis from the PREVAIL Open-Label Safety Study
Kudrow, David

The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Academic Headache Center
Yuan, Heidi

Early Prescribing Patterns of the Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies Are Dominated by Adjunctive Use for Episodic and Chronic Migraine Prevention: Trending the First Year of US Adoption
Schobel, Virginia

The Aimovig "Wear-Off": A Retrospective Review
Feldman, Daniel

Patient Engagement and Patient Centered Research: The Results of Four Focus Groups on the Migraine Patient Experience During Research Studies and Their Ideas for Study Design Consideration in Future Studies
Minen, Mia

Impact of US Physicians’ Perceptions of the Distinct Pharmacological and Clinical Characteristics of the Novel Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Self-Reported Chronic Migraine Prevention Brand Share
Schobel, Virginia

Effectiveness of Erenumab-aooe on High Frequency Migraine Patients in a Tertiary Center
Preston, Juliette

Detecting Factors Associated with “low” and “high” Headache Pain Days in Individuals with Chronic Migraine
Donoghue, Stephen

Longitudinal Preventive Medication Use Patterns in Patients Receiving OnabotulinumtoxinA Treatment: A Chart Review Study
Burch, Rebecca

Tolerability of Three Additional Neck Injection Sites During OnabotulinumtoxinA Therapy Following the PREEMPT Injection Paradigm for Chronic Migraine
Khan, Fawad
P27 Up in Smoke: Erenumab Induced Nausea Exacerbated by Smoking Resulting in Smoking Cessation
Mathew, Paul

P28 A Survey of American Headache Society Members on Treatment of Migraine in Pregnancy
Hamilton, Katherine

P29 Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors
Kiarashi, Jessica

P30 DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Efficacy
Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Lipton, Richard

P31 Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD® Device Compared to
D.H.E. 45® for Injection from the STOP 101 Clinical Trial
Craig, Karen

P32 The Medication Overuse Treatment Strategy (MOTS) Trial: Description of the Patient Cohort at Baseline
Schwedt, Todd

P33 Galcanezumab Safety/tolerability Profile Does Not Differ in Patients with Episodic or Chronic Migraine
Stauffer, Virginia

P34 Real-World Experience with CGRP-antagonists in the Treatment of Migraine
Bucklan, Julie

P35 Long-Term Safety of Fremanezumab: Results of a 1-Year Study
Ning, Xiaoping

P36 Control of the Placebo Response in Migraine Induction Models
CONNELL, JOHN

P37 Safety, Tolerability and Comparative Pharmacokinetics of a Novel, Dry Powder Intranasal DHE Product
(STS101)
Albrecht, Detlef

P38 Post-Market Observational Study of Patient Experience with Erenumab
Robblee, Jennifer

P39 Changes in MIDAS, Perceived Stress, Frontalis Muscle Activity and NSAID Usage in Patients with
Migraine Headache Without Aura Following Ayurveda and Yoga Compared to Controls: An Open Labeled
Non-randomized Study
Sharma, Vasudha

P40 Treatment of Trigeminal Neuralgia Using the TX360 Device
Freitag, Frederick

P41 Rimegepant 75 Mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc
Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine
Croop, Robert

P42 Riboflavin and Micronutrient Deficiencies in Patients with Migraine--A Case Series with Documented
Blood Levels and Response to Treatment of Nutritional Deficiencies
Achari, Madhureeta

**P43**
The Effectiveness of Essential Oils on Headaches
Sheikh, Huma

**P44**
STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD®) Device] in Migraine Headache
Shrewsbury, Stephen

**P45**
The Impact of Shift Work on Migraine: A Case Series and Literature Review
Sandoe, Claire

**P46**
Safety and Tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Safety Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Munjal, Sagar

**P47**
Cluster Headache Is One of the Most Painful Human Conditions: Epidemiology of Cluster Headache and Probable Cluster Headache from a Large International Sample
Burish, Mark

**P48**
Vascular Risk Associations in Cluster Headache: A Case Control Study from India
Chowdhury, Debashish

**P49**
The Headache That Broke My Heart
Singh, Jyotika

**P50**
Symptomatic SUNA Heralding a Lateral Medullary Infarction: A Case of a Sentinel Trigeminal Autonomic Cephalgia
Robblee, Jennifer

**P51**
Prevalence of Gastric Ulcer Disease (UD) and Association with NSAID Use Among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment (MAST) Study
Lipton, Richard

**P52**
Understanding Practice Patterns Surrounding the Use of Hormonal Therapies in Migraine: results from the Women’s Health Migraine Survey
Grosberg, Brian

**P53**
Who Is Eligible for Novel Medications Designed for the Acute Treatment of Migraine and What Are Their Unmet Needs? Results of the OVERCOME Study
Lipton, Richard

**P54**
Impact of Migraine Headache Day Frequency on Associated Health: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
Lipton, Richard

**P55**
Identifying Sociodemographics and Symptoms Associated with Emergency Department and Urgent Care Use in People with Migraine: Survey Results from Migraine in America Symptoms and Treatment Study
Schwedt, Todd
Symptom Patterns, Disability, and Physician Visits Among a US Sample of People with Migraine: Results of the OVERCOME Study
Reed, Michael

A Real-World Analysis of the Burden of Migraine in Patients with Prior Treatment Failure: Evidence from the BECOME Study
Lucas, Christian

Meaningful Relief Measurement: Analysis of Responses to a Survey of Patient Priorities
Smith, Timothy

Headache Evaluation and Treatment: results from the Women’s Health Migraine Survey
Grosberg, Brian

Evaluating the Relationship of Healthcare Professional-Patient Communication, Treatment and Satisfaction: Results from Migraine in America Symptoms and Treatment Study
Buse, Dawn

Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
Alam, Aftab

Characteristics of Migraine Patients Visiting the European Headache Specialist Centers: Real-World Evidence from the Multinational BECOME Study
Pozo-Rosich, Patricia

Migraine Prevalence, Disease and Comorbidity Burden, and Evidence-based Practice Guideline Knowledge: results from the Women’s Health Migraine Survey
Minen, Mia

Factors Associated with Most Bothersome Non-Headache Migraine Symptom (Nausea, Photophobia and Phonophobia): Results from the Migraine in America Symptoms and Treatment (MAST) Study
Munjal, Sagar

Assessment of Prevalence and Knowledge Knowledge of Migraine Headache in Northeast Nigeria
Ali, Mohammed

Network Analysis of the International Classification of Headache Disorders, 3rd Edition
Zhang, Pengfei

A Surveillance of the Tortuous Path from Primary Care to Headache Specialist
Lin, Jason

Prevalence and Incremental Healthcare Costs of Comorbid Depression in Migraine Care
Kee, Arianna

Digital Therapeutics Treatment of Migraine
Schenker, Eran

Epidemiology of Headache in Latin America: A Systematic Review and Meta-analysis of Its Prevalence and Incidence
Pacheco-Barrios, Kevin
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P71</td>
<td>10-Year Cost-Effectiveness Analyses of Fremanezumab as Preventive Treatment in Chronic and Episodic Migraine</td>
<td>Smolen, Lee</td>
</tr>
<tr>
<td>P72</td>
<td>A RETROSPECTIVE COMMUNITY BASED STUDY EVALUATING DISABILITY in MIGRAINE PATIENTS TREATED with ERENUMAB-aooe</td>
<td>Turner, Ira</td>
</tr>
<tr>
<td>P73</td>
<td>Economic Aspects of Establishing Prior Use of Two Oral Triptans Before Starting Novel Acute Treatments for Migraine</td>
<td>Pohl, Gerhardt</td>
</tr>
<tr>
<td>P74</td>
<td>Impact of Migraine on the Prevalence and Clinical Presentation of Depression: A Population-based Study</td>
<td>Chu, Min Kyung</td>
</tr>
<tr>
<td>P75</td>
<td>Development of a Patient Reported Outcome Measure Evaluating Meaningful Response to Migraine Treatment</td>
<td>Cady, Ryan</td>
</tr>
<tr>
<td>P76</td>
<td>Systematic Review of Clinical Studies Evaluating Non-invasive Neuromodulation for Migraine and Cluster Headache</td>
<td>Reuter, Uwe</td>
</tr>
<tr>
<td>P77</td>
<td>Scoping Review of Migraine and Air Pollution Studies</td>
<td>Portt, Andrea</td>
</tr>
<tr>
<td>P78</td>
<td>Association of Migraine and Asthma in Pediatric Patients: A National Perspective on Gender and Racial Disparities</td>
<td>Patel, Riddhiben</td>
</tr>
<tr>
<td>P79</td>
<td>Benign Paroxysmal Torticollis: Phenotype, Natural History and Future Research Directions</td>
<td>Greene, Kaitlin</td>
</tr>
<tr>
<td>P80</td>
<td>Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children</td>
<td>VASUDEVAN, PAVITHRA</td>
</tr>
<tr>
<td>P81</td>
<td>Pediatric Screen Exposure and Headache Disability</td>
<td>Langdon, Raquel</td>
</tr>
<tr>
<td>P82</td>
<td>Efficacy of Sphenopalatine Ganglion Blocks in a Pediatric Headache Practice</td>
<td>Holick, Michelle</td>
</tr>
<tr>
<td>P83</td>
<td>Prognosis of New Daily Persistent Headache in Children and Adolescents</td>
<td>Simmons, Adrienne</td>
</tr>
<tr>
<td>P84</td>
<td>Title: Headache Prevalence in Transgender Youth: A Retrospective Chart Review</td>
<td>Hranilovich, Jennifer</td>
</tr>
<tr>
<td>P85</td>
<td>Headache Frequency in Children After Hemispherectomy</td>
<td>Pandit, Ishani</td>
</tr>
<tr>
<td>P86</td>
<td>A Curious Case of Headache</td>
<td>Pai B.H, Poonam</td>
</tr>
</tbody>
</table>
Responder Rates to Atogepant in Patients with Episodic Migraine: A Post Hoc Analysis of Results from a Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled Trial
Dodick, David

Safety and Tolerability of Ubrogepant Following Intermittent, High-Frequency Dosing
Goadsby, Peter

Opioid Use, Rebound Headache, and Resource Utilization Among Migraine Patients with Insufficient Response to Triptans Based on Real-World Data
Shewale, Anand

Triptan Discontinuation and Treatment Patterns Among Migraine Patients Initiating Triptan Treatment in a United States Commercially Insured Population
Marcus, Steven

Analysis of Treatment Change of Acute Prescription Migraine Medications Using Real-World Evidence
Lipton, Richard

Greater Headache-Related Burden and Disability Among Those with Medication Overuse: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Schwedt, Todd

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults
Jakate, Abhijeet

Health-Related Quality of Life Based on Response to Triptans in People with Migraine: Analysis of Real-World Data
Lipton, Richard

Coadministration of Single Therapeutic Oral Doses of Ubrogepant and Sumatriptan Produces No Clinically Relevant Pharmacokinetic Interactions
Jakate, Abhijeet

Single Therapeutic Doses of Ubrogepant Are Not Associated with a Clinically Relevant Drug-Drug Interaction When Co-administered with Acetaminophen or Naproxen
Jakate, Abhijeet

Absence of Clinically Significant Drug Interactions with Co-administration of Atogepant and an Ethinyl Estradiol–Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
Ankrom, Wendy

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene–Related Peptide Receptor
Moore, Eric

 Educating Patients on New Treatments: The Experience of One Headache Center’s Launch of the New CGRP Migraine Medications
Wells, Rebecca
Absence of Clinically Significant Drug Interactions with Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
Li, Chi-Chung

Pressing Issues Among New Investigators and Trainees in Headache: Results of a Survey of the American Headache Society New Investigator and Trainee Section and International Headache Academy Attendees
VanderPluym, Juliana

A Proposed Structure for the Study of the History of Headache Medicine
Rosen, Noah

Ubrogepant Achieves Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine
Dodick, David

Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine
Vasudeva, Raghavendra

Efficacy and Safety of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the Multicenter, Randomized, Placebo-controlled FOCUS Study
Ferrari, Michel

Effect of a Rescue or Recurrence Dose of Lasmiditan on Efficacy and Safety in the Acute Treatment of Migraine: Findings from the Phase 3 Trials (SAMURAI and SPARTAN)
Loo, Li Shen

Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen

Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine
Rizzoli, Paul

Long-term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine Attacks
Ailani, Jessica

Long-term Response Rates in Chronic and Episodic Migraine Patients with Concomitant Preventive Medication Use: Results from 1-Year Study
Goadsby, Peter

Temporal Response Patterns to Erenumab in Patients with Chronic Migraine
Tepper, Stewart

An Optional Second Dose of Ubrogepant Is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine
Ailani, Jessica

Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study
Goadsby, Peter
Effects of Lasmiditan on Cardiovascular Parameters in Healthy Subjects Receiving Oral Doses of Propranolol
Wilbraham, Darren

Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
McAllister, Peter

Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine
Ruff, Dustin

Efficacy of Erenumab in Chronic Migraine Patients with and Without Alloodynia
Lipton, Richard

Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Lipton, Richard

Improvement in Migraine Pain Severity in Patients Treated with Erenumab
Lipton, Richard

How Adverse Events Are Collected and Reported: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
Krege, John

Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy
Buchanan, Andrew

Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
Hindiyeh, Nada

Long-Term Impact of Fremanezumab on Response Rates: Results of a 1-Year Study
Newman, Lawrence

Safety of Ubrogepant in Participants with Moderate to High Cardiovascular Risk
Hutchinson, Susan

PREVAIL: An Open-Label Phase 3 Trial to Evaluate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine
Allan, Brent

Temporal Response Patterns to Erenumab in Patients with Episodic Migraine
McAllister, Peter

Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache: Results from a Patient Registry
Liebler, Eric

The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Headaches of at Least Moderate Severity in Patients with Chronic Migraine
Silberstein, Stephen
Long-term Efficacy of Fremanezumab in Migraine Patients with and Without Concomitant Oral Preventive Medication Use: Results of a 1-Year Study
Goadsby, Peter

Long-Term Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Migraine Patients with Concomitant Preventive Medication Use: Results of a 1-Year Study
Lipton, Richard

Improvement in Response over Time with Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Halker Singh, Rashmi

Healthcare Resource Utilization in Adult Patients Treated with OnabotulinumtoxinA for Chronic Migraine: Results from the COMPEL Study
Rothrock, John

Efficacy and Safety of Lasmiditan in Patients on Concomitant Migraine Preventive Medications: Findings from SAMURAI and SPARTAN Phase 3 Trials
Schim, Jack

Comparison of Early Plasma Exposure of DHE Following Nasal, Oral Inhalation, or Intravenous Administration
Satterly, Kelsey

Efficacy Is Maintained with Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine
Lipton, Richard

Improvement in Headache-related Disability with Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the International, Multicenter, Randomized FOCUS Study
Ashina, Messoud

Sustained Response to Erenumab over Time in Patients with Episodic Migraine
McAllister, Peter

Eptinezumab Improved Health-Related Quality of Life in Patients with Chronic Migraine in the Open-Label PREVAIL Study
Kassel, Eric

The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Migraine in Patients with Episodic Migraine
Dodick, David

Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen

Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Lipton, Richard
Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Results of a 1-Year Study
McAllister, Peter

Long-Term Impact of Fremanezumab on Headache-Related Disability, Quality of Life, and Patient Satisfaction in Episodic Migraine and Chronic Migraine
Cohen, Joshua

Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine and Comorbid Moderate to Severe Depression
Lipton, Richard

Effects of Lasmiditan When Coadministered with Sumatriptan: Results of a Randomized, Double-Blind, Crossover Study in Healthy Subjects
Berg, Paul

Effects of Lasmiditan When Coadministered with Topiramate: Results of a Parallel, Placebo-Controlled, Fixed-Sequence Study in Healthy Subjects
Berg, Paul

Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Ailani, Jessica

Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications
Ferrari, Michel

Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine with Concomitant Preventive Medication Use
Goadsby, Peter

Sustained Response to Erenumab over Time in Patients with Chronic Migraine
Tepper, Stewart

Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
Winner, Paul

Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study
McAllister, Peter

Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study
Brandes, Jan

Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies
Hutchinson, Susan
Quarterly Administration of Fremanezumab Does Not Show “Wearing Off” Effect During Third Month After Injection
Blaiss, Cory

The Effect of Migraine Headache Intensity on the Efficacy of Low-Dose (3 Mg) Sumatriptan Injection (DFN-11) in the Acute Treatment of Episodic Migraine Attacks: From the RESTOR Study
Munjal, Sagar

Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
Brandes, Jan

An Open-Label Phase 3 Trial to Evaluate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine (PREVAIL): Demographics and Baseline Characteristics
Song, Yanyu

Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Results of a 1-Year Study
Brandes, Jan

Depression and Anxiety Are Associated with Increased Headache-Related Disability in Episodic and Chronic Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Lipton, Richard

Features of Episodic Cluster Headache in the Real World Setting: Clinical Characteristics from a Large, Multi-national, Cross-sectional Survey
Martinez, James

Characteristics of Headaches and Premonitory Symptoms During the Run-in Phase of a Large Migraine Trial
Schmidt, Peter

Healthcare Resource Use and Humanistic Burden Associated with Attack Frequency in Episodic Cluster Headache
Andrews, J. Scott

Characteristics of Patients Receiving Preventive Treatment Among Prevention-eligible Patients with Migraine
Foster, Shonda

Characteristics of Early Users of Erenumab in a Large US Administrative Claims Database
Chia, Victoria

Dihydroergotamine, Then and Now
Ray, Sutapa

The Association Between Migraine Headache and Objectively-assessed Sleep Among Adults with Episodic Migraine: A Prospective Cohort Study
Vgontzas, Angeliki

Does Treatment of Cervical Dystonia Reduce Migraine Frequency?
Bobker, Sarah
P169 Thoracic CSF Venous Fistula Presenting as Spontaneous Intracranial Hypotension
Duvall, Jaclyn

P170 Migraine History and Effectiveness of Caffeine Use in Hypnic Headache Patients
Preston, Juliette

P171 Non-Invasive Vagus Nerve Stimulation as a Rescue Treatment for Vestibular Migraine
Beh, Shin

P172 Observations from a Collaborative Care Headache and Hormone Clinic Model
Grosberg, Brian

P173 A Novel Perivascular Approach to the Ultrasound-guided Glossopharyngeal Nerve Block
Anugerah, Ariana

P174 Persistent Neurological Deficits in a Patient with CACANA1A Gene Revealing Diffuse Astrocytoma
Suneja, Aarushi

P175 One and Done: A Case Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia
Mathew, Paul

P176 Neuropathic Otalgia: Rare and Treatable Ear Pains
Suneja, Aarushi

P177 Red Ear Syndrome Case Report: A Rational Use of Erenumab
Robblee, Jennifer

P178 Diffuse Vasogenic Leakage of Gadolinium Contrast in Patients with Syndrome of Headache and Neurological Deficits with CSF Lymphocytosis (HANDL)
Vilanilam, George

P179 Novel Receptor Activity Mapping of Methysergide and Its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for Both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine
Guzman, Miguel

P180 Serotonin Receptor Activity Profiles (5-HT2B and 5-HT2A) for Nine Commercialized Ergot Alkaloids Correspond to Known Risks of Fibrosis and Hallucinations
Alam, Aftab

P181 Calcitonin Gene-related Peptide Inhibitor; Role in Treatment of Hemicrania Continua, with Potential Benefit in Controlling Diarrhea
Hussaini, Sharmeen

P182 Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile
Armer, Thomas

P183 Post-Traumatic Headache Is Highly Persistent over Time After TBI in Veterans
Couch, James
P184 Sports-related Concussion in High School Wrestlers: Survey of Wrestlers and Their Parents
Goldberg, Marco

P185 Understanding the Prevalence and Geographic Distribution of Headache Disorders Within the Veterans Health Administration
Grinberg, Amy

P186 New Persistent Post-Concussion Headache in Children and Adolescents
Barissi, Marcus

P187 Introducing a Nationwide Program to Improve the Care of Veterans with Headache – the Veterans Health Administration Headache Center of Excellence (HCoE) Program
Sico, Jason

P188 Results of a Gap Analysis of Headache in Veterans and Service Members
Lindsey, Hayley

P189 Dextromethorphan/Quinidine for Post Traumatic Migraine in Patients with Pseudobulbar Affect
Kozminske, Matthew

P190 Rationale and Design for a Randomized, Single-Center, Double-blind, Sham-Controlled Study of Non-invasive Vagus Nerve Stimulation for the Acute and Preventive Treatment of Post-traumatic Headache
Vargas, Bert

P191 Objectively Measured Physical Activity Among Migraineurs as a Function of Headache Activity
Rogers, Daniel

P192 Feasibility and Acceptability of Smartphone Based Migraine Behavioral Therapy in The Neurology Outpatient Setting: A Single Arm Study
Minen, Mia

P193 The Use of Mindfulness-Based Cognitive Therapy (MBCT) for Migraine for the Treatment of Depressive Symptoms in People with Migraine: Secondary Analysis Results from a Phase 2b Pilot Randomized Clinical Trial
Rosenberg, Lauren

P194 Does Message Framing Help with Willingness to Pursue Behavioral Therapy: A Study in People with Migraine
Jalloh, Adama

P195 Does Motivational Interviewing Improve Patients’ Participation in Migraine Behavioral Therapy: A Pilot Single-Blinded Randomized Controlled Trial
Minen, Mia

P196 Relationship Between Age of Onset and Psychological Factors in Migraine Patients
Sutton, Leah

P197 Development and Implementation of “The Migraine Toolbox”
bernstein, carolyn

P198 Integrating Physical and Mental Health in Patients with Headache: Bridging the Gap via a Transdisciplinary and Interprofessional Approach
Amorello, Brian
Assessing Diagnostic Error in Cerebral Vein Thrombosis via Detailed Chart Review
Liberman, Ava

A Rare Case of Bilateral Internal Carotid Artery Aneurysms Presenting as Trigeminal Neuralgia
Muzammil, Syeda maria

The Presence of Headache Attributed to TMD Is Associated with Greater Psychiatric Comorbidity in Patients with Chronic TMD
Vivaldi, Daniela

Migraine Treatments Utilized by Postural Orthostatic Tachycardia Syndrome Patients
Fayyaz, Tabassum

Squamous Cell Carcinoma as a Delayed Presentation of Supraorbital Neuralgia and Multiple Cranial Neuropathies: A Case Report
Robblee, Jennifer

“Ear Burn” as a Positional Manifestation of Gastroesophageal Reflux Disease
Arca, Karissa

Recurrent Thunderclap Headache from a Sexual Performance Enhancing Agent Marketed as All-natural
Sallom, Yamin

Lumbar CSF Pressure vs Volume Studies May Provide Clues to Occult Underlying Pathology Associated with Headache
Lucchese, Scott

Headaches in a HIV Patient
Varma-Doyle, Aditi

The function of the brain that turn dysfunctional in migraine and related functional disorders
Hougaard, Kjeld

Analgesic effect of intranasal oxytocin in a rat model of trigeminal neuralgia
Yeomans, David

The Aimovig “Wear-Off”: A Retrospective Case Series of Response to 14 day Dosing
George, Naveen

IV Valproate Sodium as a Preventive Treatment for Chronic Migraine
Riggins, Nina

Prognosis following discontinuation of onabotulinumtoxinA therapy in "super-responding" chronic migraine patients
Rothrock, John

Content validity of the HIT-6 in migraine patients: results of a systematic literature review
Houts, Carrie

Chronic migraine: Establishing a responder definition for the HIT-6 total score
Cady, Roger
Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total Score Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial
Lipton, Richard

Early and Sustained Reduction in Headache Impact in People with CM After Eptinezumab Treatment: HIT-6 Item Analysis in the Phase 3 PROMISE-2 Trial
Buse, Dawn

Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
Winner, Paul

Eptinezumab Reduces the Frequency of Acute Medication Usage in Patients with Episodic or Chronic Migraine
Tepper, Stewart

Treatment with Eptinezumab Demonstrated Meaningful Improvements in Patients with Chronic Migraine Experiencing a High Frequency of Severe Migraines
Nagy, Abraham

The Eptinezumab:CGRP Complex Structure and Characterization of the Ligand Binding Interface
Misura, Kira

Development of nasal insulin-like growth factor-1 as a novel treatment for migraine
Kraig, Richard

Use of Single Pulse Transcranial Magnetic Stimulation (sTMS) to treat migraine with medication overuse: response over time
DiGuilio, Susan

Chronic Migraine is Highly Prevalent in General Otolaryngology; A CHEER Network Study
Teixido, Michael

Is stress associated with pain severity in chronic migraine?
Donoghue, Stephen

A Patient perspective of Complementary and Integrative Medicine (CIM) for Migraine Treatment: A social media survey
Kuruvilla, Deena

A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura
Armanious, Mark

Facial temperature change after Sphenopalatine ganglion block in Primary Headache Disorders
Mathew, Shema

Migraine Modifies Propranolol Efficacy for Treatment of TMD Pain: SOPPRANO Randomized Controlled Trial
Tchivileva, Inna

Limited antinociceptive effects of delta-9-tetrahydrocannabinol in experimental models of capsaicin-induced hyperalgesia and acute pain in healthy human volunteers
Schindler, Emmanuelle

P230LB  Assessing the Long-Term Effectiveness of Qtrypta using the Migraine-ACT: Correlation with Electronic Diary Scores
  Tepper, Stewart

P231LB  Individual-level patterns of perceived stress throughout the migraine cycle: A longitudinal cohort study using daily prospective data
  Shulman, Kenneth

P232LB  A pilot randomized controlled trial of a community-based mindfulness-based stress reduction intervention versus usual care for moderate-to-severe migraine headache
  Pressman, Alice

P233LB  Occipital neuralgia: clinical profile and sleep quality of 55 Mexican patients. Results from PREMECEF.
  Marfil, Alejandro

P234LB  Effectiveness of a Novel algorithm in the treatment of chronic migraine by reduction of work hour loss due absenteeism and presentism.
  OWIESY, FARO

P235LB  Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
  Lipton, Richard

P236LB  Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials
  Buse, Dawn

P237LB  Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays
  Conway, Charles

P238LB  Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab
  Mullin, Kathleen

P239LB  Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials
  Dodick, David

P240LB  The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
  Croop, Robert

P241LB  Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
  Croop, Robert

P242LB  A Single Dose of Rimegepant 75 mg Provides Pain Relief and Return to Normal Function: Results from 3 Phase 3 Trials in Adults With Migraine
  Lipton, Richard
An app to help children describe their headache. Results of the first clinical trial.

Nava, Nelly

Trajectory of Pediatric Migraine Preventive Medication Treatment Response: An Ancillary Study of the CHAMP Trial

Reidy, Brooke

Post-hoc outcomes from a Phase 3 randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache

Kudrow, David

Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study

Tanenbaum, Nadia

A Real Headache, Professional Subjects in Migraine Trials

Shiovitz, Thomas

Dysgeusia rates in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for acute treatment of migraine

Munjal, Sagar

Triptan-related adverse events in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of migraine

Brand-Schieber, Elimor

Evaluation of the Number of Migraine Headache Days and Hours in Subjects Using DFN-02 for Acute Treatment in a Long Term Open-label safety study

Munjal, Sagar

Daily and Economic Burden of Living with Migraine: United States Results from the “My Migraine Voice” Survey

Shah, Shweta

User Acceptance of a Prefilled Auto-injector Device for Erenumab in Patients with Migraine

Mead, Jennifer

Is chocolate associated with more severe days in chronic migraine?

Shulman, Kenneth

Early Use of Erenumab in US Real World Practice

Chia, Victoria


Shah, Shweta

Erenumab prescription early view: Patient characteristics, treatment patterns and medication adherence in the United States

Shah, Shweta
P271LB Treatment patterns, healthcare resource use, and outcomes of patients with chronic and episodic migraines treated with erenumab: a multicenter chart-review study Chandler, David

P272LB Patient satisfaction with fremanezumab treatment for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study Lipton, Richard

P273LB Simulated Use of a Fremanezumab Autoinjector: Use as Intended, Ease of Use, and Comfort with Using the Autoinjector Cowan, Robert

P274LB Patient preference for dosing regimen and perception of dosing flexibility with fremanezumab for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study Cowan, Robert

P275LB A rare case of nervus intermedius neuralgia responsive to sphenopalatine ganglion blocks Joseph, Rosamma

P276LB Rare Cause of Worsening Migraine with Aura: Iatrogenic Atrial Septal Defect Following Cardiac Ablation Thaler, Alison

P277LB The Effect of Aimovig on Trigeminal Neuralgia: A Retrospective Case Series George, Naveen

P278LB Migraine Features Associated with Postural Orthostatic Tachycardia Syndrome (POTS) Mueller, Bridget

P279LB The degree of discomfort provoked by flickering light is strongly related to visual cortex response Patterson Gentile, Carlyn

P280LB Phase 1 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range Conway, Charles

P281LB Response to Mindfulness-Based Cognitive Therapy for Migraine in Chronic and Episodic Migraine: Planned Secondary Analyses of a Randomized Clinical Trial Seng, PhD, Elizabeth

P282LB Spontaneous Intracranial Hypotension (SIH) Secondary to CSF Venous Fistula: Case Series Duvall, Jaclyn

P283LB Risk Factors for Secondary Headache in Children and Adolescents: A Systematic Review Velasquez, Gerardo